Metabolic syndrome as a peculiar target for management of prostate cancer patients

Vincenza Conteduca, Giuseppe Di Lorenzo, Giovanni Bozza, Raffaele Ardito, Michele Aieta

Research output: Contribution to journalArticlepeer-review


An interesting and reciprocal association between the metabolic syndrome and prostate cancer has been identified. Metabolic alterations, such as hyperinsulinemia, increased levels of insulin growth factor-1, and insulin resistance could be on the basis of development and progression of many tumors, including prostate cancer, and changes in body composition, in turn, can represent some side effects of androgen deprivation therapy and novel drugs, such as mammalian target of rapamycin inhibitors. This review evaluates this interrelation between metabolic syndrome and prostate tumor scanning in many clinical and preclinical epidemiological studies and describes possible pathogenetic biological mechanisms. Finally, this article discusses feasible clinical implications for the management, prevention, diagnosis, prognosis, and treatment of patients affected by metabolic syndrome and prostate cancer, with particular attention to the metformin action.

Original languageEnglish
Pages (from-to)211-220
Number of pages10
JournalClinical Genitourinary Cancer
Issue number3
Publication statusPublished - Sept 2013


  • Androgen deprivation therapy
  • Carcinogenesis
  • Hyperinsulinemia
  • Insulin-growth factor-1
  • Metformin

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Metabolic syndrome as a peculiar target for management of prostate cancer patients'. Together they form a unique fingerprint.

Cite this